Editorial note: this article summarises published research on DSIP. Baclabs does not sell DSIP or any peptide; we supply bacteriostatic water and reconstitution consumables. Nothing here is medical advice.
DSIP, delta sleep-inducing peptide, has one of the most evocative names in the peptide world and one of the least settled evidence bases. It was named for an apparent ability to promote slow-wave (delta) sleep, but nearly fifty years after its discovery, researchers still disagree about whether it is truly a sleep factor at all. This article covers what DSIP is, the isolation story, why its role is contested, what the human sleep trials actually found, and how to read the common dsip peptide dosage for sleep search against a frank account of the evidence.
DSIP is not a licensed medicine in the UK or elsewhere, and no modern controlled trials support its use.
What DSIP is and where it came from
DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of about 849 Da. It was isolated by the Schoenenberger–Monnier group in Basel in 1977, recovered from the cerebral venous blood of rabbits during electrical stimulation of the thalamus that induced sleep [1]. The team characterised and synthesised the peptide, and the synthetic version reproduced the delta-EEG and sleep-spindle enhancement seen with the natural material after intraventricular infusion [2]. That origin, a substance appearing in the blood of a sleeping animal and reproducing sleep-like EEG changes, is what gave DSIP its name and its early promise.
Why its role as a sleep peptide is contested
The complication is that DSIP never behaved like a clean sleep hormone. Over subsequent decades it was linked to a long and disparate list of actions, effects on stress hormones, temperature regulation, pain, and circadian rhythm, that do not obviously fit a single sleep-promoting role. A 2006 review summarised the situation bluntly, calling DSIP “a still unresolved riddle” and noting that its many functions have resisted a unifying explanation [3]. Work on its diurnal rhythm in humans even found plasma DSIP correlated positively with body temperature and negatively with REM and slow-wave sleep, the opposite of what a simple sleep-promoting factor would predict [4]. So the name oversells a mechanism that was never firmly established.
The human sleep trials: what they found
A cluster of small studies in the 1980s and early 1990s tested DSIP in chronic insomniacs, mostly by intravenous injection. The results are mixed, and the studies are small and old:
| Study | Design and dose | Reported result |
|---|---|---|
| Double-blind, 16 insomniacs [5] | Matched-pairs, parallel groups | Higher sleep efficiency, shorter sleep latency with DSIP |
| Middle-aged/elderly insomniacs [6] | 6 × 30 nmol/kg IV over one week | Improvement toward normal sleep, with late effects at follow-up |
| 6 middle-aged insomniacs [7] | 25 nmol/kg IV, acute | Longer sleep duration, higher quality, fewer interruptions |
| Open study, 7 severe insomniacs [8] | Series of 10 injections | Sleep normalised for 3–7 month follow-up in most |
Set against these are studies where effects were modest or difficult to reproduce, and the field’s own reviews describing the sleep evidence as inconsistent [3]. Taken together, the picture is of a peptide that showed some signal in small, dated trials but never accumulated the robust, replicated, modern evidence that would justify calling it an effective sleep aid.
DSIP dosage for sleep: the literature figures
For the dsip peptide dosage for sleep question, the honest answer pairs the reported numbers with a strong evidence caveat. In the human insomnia studies above, DSIP was given intravenously at roughly 25–30 nmol/kg body weight, sometimes as single pre-sleep injections and sometimes as short repeated courses [6][7][8]. On a nanomole-per-kilogram basis those are small quantities of peptide. These are figures as used in the cited trials, not a recommended dose: the studies were small, decades old, used intravenous administration under supervision, and have not been confirmed by modern controlled trials. There is no established, validated DSIP dose for sleep, and DSIP is not a licensed treatment. Anyone presenting a precise milligram bedtime dose as established is going beyond what the literature supports.
Reconstitution maths for a 5 mg DSIP vial
DSIP is supplied as lyophilised powder. As with any peptide, concentration is mass divided by diluent volume:
| DSIP vial | Diluent added | Concentration | Per U-100 unit (0.01 mL) |
|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL = 5,000 mcg/mL | 50 mcg |
| 5 mg | 2 mL | 2.5 mg/mL = 2,500 mcg/mL | 25 mcg |
| 5 mg | 2.5 mL | 2 mg/mL = 2,000 mcg/mL | 20 mcg |
So a 5 mg vial reconstituted with 2 mL of diluent gives 2,500 mcg/mL; each unit on a U-100 insulin syringe then holds 25 mcg, and 10 units (0.1 mL) hold 250 mcg. The total mass in the vial does not change with more diluent, only how many units correspond to a given quantity. Because the trial doses were expressed per kilogram of body weight rather than as fixed amounts, converting them requires the participant’s weight and the study’s units, another reason the published figures do not translate into a simple bedtime dose.
Diluent choice and storage
A multi-dose vial that will be punctured repeatedly needs a preserved diluent. Baclabs supplies UK-stocked bacteriostatic water in 30 mL vials; the reconstitution guide sets out the method and maths. The benzyl alcohol preservative is the reason a bacteriostatic vial is generally treated as usable for up to 28 days after first puncture when refrigerated, see storage and shelf life. while the difference between preserved and preservative-free diluent is covered in bacteriostatic versus sterile water. For the wider group, see the cognitive peptides pillar; for a related pineal-linked compound, see Epithalon and Pinealon.
Frequently asked questions
Does DSIP actually help you sleep?
The evidence is mixed. Small, old studies in chronic insomniacs reported improved sleep efficiency and shorter latency at intravenous doses around 25–30 nmol/kg [5][7], but findings were inconsistent and a major review questioned whether DSIP is a sleep peptide at all [3]. There are no modern controlled trials, so it cannot be called a proven sleep aid.
What is the DSIP dosage for sleep?
In the cited human trials, DSIP was given intravenously at roughly 25–30 nmol/kg body weight, as single pre-sleep injections or short courses [6][7][8]. These are figures from small, decades-old studies under supervision, not a validated or recommended dose. No established DSIP sleep dose exists, and DSIP is not a licensed medicine.
Why is DSIP called a sleep peptide if the evidence is unclear?
It was named in 1977 after appearing in the blood of sleeping rabbits and reproducing delta-sleep EEG changes when infused into the brain [1][2]. Later research found it has many unrelated actions and does not behave like a straightforward sleep hormone, which is why one review called it “a still unresolved riddle” [3]. The name reflects its discovery, not a settled mechanism.
How do you reconstitute a 5 mg DSIP vial?
Divide the mass by the diluent volume. A 5 mg vial with 2 mL gives 2.5 mg/mL (2,500 mcg/mL), so each unit on a U-100 syringe holds 25 mcg and 10 units hold 250 mcg. Adding more diluent only changes how many units equal a given amount; the total 5 mg in the vial stays the same.
Is DSIP legal in the UK?
DSIP holds no UK marketing authorisation and cannot be sold or supplied as a medicine under the Human Medicines Regulations 2012 [9]. Sold as a “research chemical,” it falls outside the licensed system, with no regulated quality, purity or safety oversight.
References
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Amino Acids, 2006
- Characterization of a delta-electroencephalogram (sleep)-inducing peptide. PNAS, 1977
- Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Experientia, 1984
- Diurnal rhythm of plasma delta-sleep-inducing peptide in humans. J Sleep Res, 1994
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. 1992
- Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. 1986
- The influence of synthetic DSIP on disturbed human sleep. 1981
- A clinical trial with DSIP. 1984
- The Human Medicines Regulations 2012, regulation 46. legislation.gov.uk
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Bacteriostatic water is supplied for reconstitution of substances intended for research and for use as directed by a healthcare professional. Peptides and medicines discussed here may be unlicensed in the UK or prescription-only; consult a qualified clinician before using any medicine. Baclabs does not sell peptides.